TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with an $8 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
- Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
- Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST
- Milestone Pharmaceuticals receives FDA approval of CARDAMYST
- Milestone Pharmaceuticals trading halted, news pending